Drug Discovery
Trusted by
- Antler
- Boost VC
The Gap Nexus Closes
Personalized medicine has been a research promise for twenty years. It has never been a manufacturing capability
Custom Peptides
Screen and formulate in the same loop
Custom Medication
Screen and formulate in the same loop
Nexus Three
Live · San DiegoOur production platform today. A working, enclosed robotic line that selects among dozens of compounds, executes custom doses, and manufactures one-of-one formulations at industrial speed.
- 24kFormulations manufactured to date
- 1MFormulations/month, current capacity basis
- ± 3%Per-compound dosing accuracy
- Compound library
- 42
- Formulation combinations
- ~10.000.000
- Dosing precision
- ± 3%
- Fill/finish
- Automated
- Quality control
- Closed-loop weight sensors
- Manufacturing standard
- cGMP-aligned
Nexus Four
In DevelopmentIndustrialized non-sterile compounding for pharmacy and pharmaceutical partners. Solids, liquids, and capsule/tablet workflows, running on one validated robotic cell instead of a row of manual stations.
- 1MFormulations/month, engineering target
- 6Racks, reference configuration
- 8/50/8Solid / liquid / pill-capsule compounds
- Primary scope
- Non-sterile ingredients
- Capacity
- 1M+
- Rack architecture
- Hybrid
- Reference configuration
- 6 Racks
- Regulatory design intent
- 21 CFR Part 11
- Connectivity
- API
Nexus Five
Coming SoonSterile and pharmaceutical-scale personalization. The same Nexus architecture, extended into the most demanding product classes — peptides, injectables, and other high-control applications.
- ISO 5Target critical-zone environment
- 4+Candidate application classes
- 503A/BRegulatory pathways supported
- Target environment
- ISO 5
- Candidate applications
- Peptides, injectables +
- Regulatory pathway
- 503A, 503B
- Validation sequence
- FAT/SAT/IQ/OQ/PQ
A New Standard For Compounding
Nexus automates the most labor-intensive parts of compounding, reducing manual work by up to 80%.
FAQ
you to*
Nexus is CLD-9's modular robotic production platform for personalized medicine — an enclosed, roughly car-sized manufacturing cell that turns an approved digital formulation into a physical, verified, one-of-one dose. It selects the right qualified components, executes each dispensing and processing step, checks its own work with sensors and mass data, and produces a complete digital record of what happened.
People also asked
We build the industrial infrastructure layer for personalized medicine — the robotics, control software, and compliance tooling that let pharmacies, telehealth companies, research teams, and pharmaceutical partners manufacture customized products on demand. We don't replace pharmacists, quality units, or clinical judgment; we replace the manual weighing, measuring, mixing, and documentation work that stands between an approved formulation and a finished dose.
Same core architecture, different stages of qualification. Nexus 3 is our operating platform today, live in San Diego. Nexus 4 industrializes nonsterile compounding — solids, liquids, and capsule/tablet workflows — for pharmacy and pharmaceutical partners. Nexus 5 extends the platform into sterile and pharmaceutical-scale personalization, targeting an ISO 5-capable environment for peptides, injectables, and other high-control applications.
Each rack is configured for up to 8 solid compounds, up to 50 liquid compounds, or up to 8 pill/capsule compounds, and a single machine can combine multiple rack types. The current platform actively manages roughly 42 compounds, with a library of tens of millions of possible formulation combinations — and capacity expands by adding qualified racks, not by rebuilding the line.
Nexus targets 1–5% per-compound dosing accuracy on the current platform, using proprietary dose cavities, indexed motion, and closed-loop weight verification. Final, product-specific accuracy and acceptance criteria are established during process characterization and qualification for each formulation.
No machine is "compliant" on its own — compliance is a property of the complete validated operating system: equipment, facility, software, process, people, and quality unit together. Nexus is engineered to support the frameworks that govern our partners' operations, including 21 CFR Part 11 electronic records, Parts 210/211 drug CGMP, Part 111 dietary-supplement CGMP, and USP <795>/<797>/<800>, depending on the product and process. Every deployment is qualified and validated for its specific intended use.
No. Nexus is a manufacturing and execution platform, not an autonomous release authority. Pharmacist oversight, the quality control unit, analytical testing, environmental monitoring, and final release decisions stay with our licensed partners. Nexus supplies the machine and the evidence trail; the people and processes around it keep full clinical and regulatory accountability.
That's what Nexus 5 is built for — sterile and pharmaceutical-scale personalization, targeting an ISO 5-capable critical processing environment with validated aseptic or closed-system modules. Candidate applications include peptide workflows, select injectables, and nasal products, with the exact regulatory pathway (503A, 503B, conventional drug manufacturing, or research use) defined case by case.